This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human beta 2-Microglobulin / B2M Protein, His Tag
catalog :
B2M-H5225
quantity :
100 ug, 1 mg
price :
250 USD, 1440 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
B2M-H5225
product name :
Human beta 2-Microglobulin / B2M Protein, His Tag
quantity :
100 ug, 1 mg
price :
250 USD, 1440 USD
quantity & price :
$250/100ug,$1440/1mg
target :
beta 2-Microglobulin
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human B2M, His Tag (B2M-H5225) is expressed from human 293 cells (HEK293). It contains AA Ile 21 - Met 119 (Accession # P61769-1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>98% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human B2M, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 98%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
β2 microglobulin is also known as Beta-2-microglobulin (B2M), is a component of MHC class I molecules which belongs to the beta-2-microglobulin family. B2M is present on all nucleated cells (excludes red blood cells). B2M associates not only with the alpha chain of MHC class I molecules, but also with class I-like molecules such as CD1 and Qa. An additional function of B2M is association with the HFE protein, together regulating the expression of hepcidin in the liver which targets the iron transporter ferroportin on the cytoplasmic membrane of enterocytes and macrophages for degradation resulting in decreased iron uptake from food and iron release from recycled red blood cells respectively. Loss of this function causes iron excess and hemochromatosis. Defects in B2M are the cause of hypercatabolic hypoproteinemia (HYCATHYP).
References :
(1) Güssow D., et al., 1987, J. Immunol. 139 (9): 3132–8.
(2) Gorevic P.D., et al., 1986, Proc. Natl. Acad. Sci. U.S.A. 83:7908-7912.
(3) Argiles A., et al., 1992, Nephrol. Dial. Transplant. 7:1106-1110.
(4) Momoi T., et al., 1995, Clin. Chim. Acta 236:135-144.
(5) Collins E.J., et al., 1995, Proc. Natl. Acad. Sci. U.S.A. 92:1218-1221.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments